

- Delfino A, Picciotto A: Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. *Clin Exp Immunol* 136:507–512, 2004
7. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC: Detection of type 2-like T helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. *Hepatology* 25:449–458, 1997
 8. Eckels DD, Tabatabail N, Bian TH, Wang H, Muheisen SS, Rice CM, Yoshizawa K, Gill J: In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation. *Hum Immunol* 60:187–199, 1999
 9. Masaki N, Fukushima S, Hayashi S: Lower th1/th2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. *Dig Dis Sci* 47:2163–2169, 2002
 10. Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G, Abrignani S: Activation of naive B lymphocytes via CD81, a pathogenic mechanism for hepatitis C virus-associated B lymphocyte disorders. *Proc Natl Acad Sci U S A* 102:18544–18549, 2005
 11. Sanyal AJ, Chand N, Comar K, Mirshahi F: Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease (Abstract). *Hepatology* 40 (Suppl. 1):179A, 2004

A Clinical Screening Tool Identifies Autoimmune Diabetes in Adults

Response to Furlanos et al.

Fourlanos et al. (1) report on a screening instrument designed to facilitate management of latent autoimmune diabetes of adults (LADA). They assert that in poorly controlled type 2 patients exhibiting two or more of five features (age <50 years, hyperglycemic symptoms, BMI <25.0 kg/m², and personal and family history of autoimmunity), the “logical” next step is confirmatory islet antibody testing (1).

Although the effect of routine use of the instrument on outcomes such as HbA_{1c} is unknown, the article raises important questions relating to the manage-

ment of clinically diagnosed type 2 diabetes. The authors state that LADA patients can require rapid escalation of oral therapy or early commencement of insulin (1). However, patients with severely deficient β -cell function but insufficient LADA features still need insulin therapy. In addition, some LADA patients achieve reasonable initial glycemic control with oral agents (2), with insulin available should this strategy fail.

We have concerns that the LADA instrument fails to meet the necessary criteria for a valid screening tool (3). In their small study, Furlanos et al. report a sensitivity of 90% and specificity of 71%. However, the positive predictive value is 21%, indicating that the probability of correctly diagnosing LADA is low. This, and the high false-positive rate (28%), suggest a limited ability to identify patients most in need of early insulin therapy.

The authors' apparent intention is to promote the instrument as part of usual care. Because of this, and since the American Diabetes Association does not recommend islet antibody testing in type 2 diabetes (4), why do the authors recommend serological confirmation (1)? Even in the case of children, in whom education, dietary counsel, and treatment differ markedly by diabetes type, autoantigens may be present in a substantial number with otherwise straightforward type 2 diabetes (4). One reason for antibody testing may be to characterize LADA patients fully for intervention studies (1), but this would only be appropriate in specialist centers.

We contend that the management of poorly controlled type 2 diabetes in adults should be based on detailed clinical assessment (including the LADA instrument components), review of glycemic control, implementation of strategies (including educator and dietitian input) that might improve adherence to self-management, a discussion of available therapies (including insulin), and adequate monitoring and support. The use of the LADA instrument and/or autoantibody testing appears redundant in this setting.

TIMOTHY M.E. DAVIS, FRACP¹
CAROLE A. CULL, PHD²
RURY R. HOLMAN, FRACP²

From the ¹School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia; and the ²Diabetes Trial Unit, University of Oxford, Oxford, Oxfordshire, U.K.

Address correspondence to Prof. Tim Davis,

School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, P.O. Box 480, Fremantle, Western Australia, 6959, Australia. E-mail: tdavis@cylle.uwa.edu.au.

DOI: 10.2337/dc06-1321

© 2006 by the American Diabetes Association.

References

1. Furlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG: A clinical screening tool identifies autoimmune diabetes in adults. *Diabetes Care* 29:970–975, 2006
2. Davis TM, Wright AD, Mehta ZM, Cull CA, Stratton IM, Bottazzo GF, Bosi E, Mackay IR, Holman RR: Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). *Diabetologia* 48:695–702, 2005
3. Barratt A, Irwig L, Glasziou P, Cumming RG, Raffle A, Hicks N, Gray JAM, Guyatt GH: Users' guide to the medical literature. XVII. How to use guidelines and recommendations about screening. *JAMA* 281:2029–2034, 1999
4. American Diabetes Association: Standards of medical care in diabetes (Position Statement). *Diabetes Care* 29 (Suppl. 1):S4–S42, 2006

A Clinical Screening Tool Identifies Autoimmune Diabetes in Adults

Response to Davis et al.

We thank Davis et al. (1) for their comments regarding the recent publication of a clinical screening tool for latent autoimmune diabetes in adults (LADA) (2). It is appreciated that the authors' routine management of “poorly controlled adult type 2 diabetes” incorporates the “LADA instrument components.” However, our observations of the management of such patients by internists and diabetes nurse practitioners in the community are often contrary to the practice of the authors. Adults with suboptimal glycemic control due to declining β -cell function (often secondary to autoimmune disease) are underrecognized, leading to delays in commencing insulin therapy. The clinical screening tool was developed to aid primary care physicians and diabetes nurse practitioners to consider the pathophysiological process of autoimmune β -cell destruction. The authors cite that the positive predictive value of the clinical screening tool is low

at 21% but do not mention that the negative predictive value of the tool is 99%; hence, the tool is highly reliable at excluding LADA and has a sensitivity of 90%, meaning that most LADA patients can be identified with the assistance of this noninvasive and cost-free clinical screening tool.

SPIROU FOURLANOS^{1,2}
LEONARD C. HARRISON¹
PETER G. COLMAN^{1,2}

From the¹Autoimmunity and Transplantation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; and the ²Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.

Address correspondence to Spiros Fourlanos, Division of Autoimmunity and Transplantation, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade Melbourne, Victoria VIC 3050, Australia. E-mail: fourlanos@wehi.edu.au.

DOI: 10.2337/dc-06-1565

© 2006 by the American Diabetes Association.

References

1. Davis TME, Cull CA, Holman RR: A clinical screening tool identifies autoimmune diabetes in adults (Letter). *Diabetes Care* 29:2560, 2006
2. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG: A clinical screening tool identifies autoimmune diabetes in adults. *Diabetes Care* 29:970–975, 2006

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)

Response to Knopp

We read with interest the results of the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)

(1). The composite primary end point rate (10 mg/day atorvastatin versus placebo) showed a hazard ratio of 0.90 (95% CI 0.73–1.12, $P = 0.34$) after 4 years. Knopp et al. (1) highlight some of the differences between ASPEN and previous atorvastatin trials (Collaborative Atorvastatin Diabetes Study and Anglo-Scandinavian Cardiac Outcomes Trial) also involving diabetic individuals without established coronary heart disease (2,3).

Other differences may also be relevant. In ASPEN, 78.3% of those on atorvastatin and 76.4% of those in the placebo group were included in the analysis. This represents a substantial “drop-out” rate. Furthermore, by the end of the study, medication was taken by 67.5% of those in the atorvastatin group and 57.6% of those in the placebo group. The “drop-in” rate in ASPEN was also high; 26.9% of those on placebo and 15.4% of those in the atorvastatin group took concomitant hypolipidemic agents. Nevertheless, LDL cholesterol was reduced by 29% with atorvastatin relative to placebo. Is it possible that among the patients on atorvastatin, some took a second statin? If so, how many of the placebo-treated patients were taking a statin and for how long?

In the ASPEN study (1), blood pressure was well controlled (mean 133/77 mmHg). The blood pressure in the Collaborative Atorvastatin Diabetes Study and the Anglo-Scandinavian Cardiac Outcomes Trial was ~138/78 and 143/80 mmHg, respectively (2,3). This difference may influence any benefit accruing from lipid lowering in ASPEN. There was also a change in protocol during the ASPEN study. Did this lead to a difference in the duration of follow-up in the primary and secondary prevention groups?

The differences outlined above, together with those mentioned by the ASPEN authors (1), may have contributed to the nonsignificant reduction in events reported in this trial.

IRENE F. GAZI, MD
DIMITRI P. MIKHAILIDIS, FRCP

From the Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College of Medicine, University of London, London, U.K.

Address correspondence to Dr. Dimitri P. Mikhailidis MD, FFPM, FRCP, FRCPATH, Reader and Honorary Consultant, Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College of Medicine, University of London, Pond Street, London NW3 2QG, U.K. E-mail: mikhailidis@aol.com.

DOI: 10.2337/dc-06-1487

© 2006 by the American Diabetes Association.



References

1. Knopp RH, D’Emden M, Smilde JG, Pocock SJ, the ASPEN Study Group: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). *Diabetes Care* 29:1478–1485, 2006
2. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 364:685–696, 2004
3. Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, the ASCOT Investigators: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA). *Diabetes Care* 28:1151–1157, 2005

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)

Response to Gazi and Mikhailidis

We appreciate the interest of Gazi and Mikhailidis (1) in the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) and their proposed reasons for the nonsignificant results (2).

We mention in our article the high rates of treatment “drop in” and “drop

Downloaded from <http://diabetesjournals.org/care/article-pdf/29/11/2560/669249/zdc011062560-a.pdf> by guest on 28 September 2022